| Literature DB >> 17618114 |
Marcus Semones1, Yanhong Feng, Neil Johnson, Jerry L Adams, Jim Winkler, Michael Hansbury.
Abstract
This communication details the evolution of the screening lead SB-203580, a known CSBP/p38 kinase inhibitor, into a potent and selective Tie2 tyrosine kinase inhibitor. The optimized compound 5 showed efficacy in an in vivo model of angiogenesis and a MOPC-315 plasmacytoma xenograft model.Entities:
Mesh:
Substances:
Year: 2007 PMID: 17618114 DOI: 10.1016/j.bmcl.2007.06.068
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN: 0960-894X Impact factor: 2.823